The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study

Elisa De Franco, Sarah E Flanagan, Jayne A L Houghton, Hana Lango Allen, Deborah J G Mackay, I Karen Temple, Sian Ellard, Andrew T Hattersley, Elisa De Franco, Sarah E Flanagan, Jayne A L Houghton, Hana Lango Allen, Deborah J G Mackay, I Karen Temple, Sian Ellard, Andrew T Hattersley

Abstract

Background: Traditional genetic testing focusses on analysis of one or a few genes according to clinical features; this approach is changing as improved sequencing methods enable simultaneous analysis of several genes. Neonatal diabetes is the presenting feature of many discrete clinical phenotypes defined by different genetic causes. Genetic subtype defines treatment, with improved glycaemic control on sulfonylurea treatment for most patients with potassium channel mutations. We investigated the effect of early, comprehensive testing of all known genetic causes of neonatal diabetes.

Methods: In this large, international, cohort study, we studied patients with neonatal diabetes diagnosed with diabetes before 6 months of age who were referred from 79 countries. We identified mutations by comprehensive genetic testing including Sanger sequencing, 6q24 methylation analysis, and targeted next-generation sequencing of all known neonatal diabetes genes.

Findings: Between January, 2000, and August, 2013, genetic testing was done in 1020 patients (571 boys, 449 girls). Mutations in the potassium channel genes were the most common cause (n=390) of neonatal diabetes, but were identified less frequently in consanguineous families (12% in consanguineous families vs 46% in non-consanguineous families; p<0·0001). Median duration of diabetes at the time of genetic testing decreased from more than 4 years before 2005 to less than 3 months after 2012. Earlier referral for genetic testing affected the clinical phenotype. In patients with genetically diagnosed Wolcott-Rallison syndrome, 23 (88%) of 26 patients tested within 3 months from diagnosis had isolated diabetes, compared with three (17%) of 18 patients referred later (>4 years; p<0·0001), in whom skeletal and liver involvement was common. Similarly, for patients with genetically diagnosed transient neonatal diabetes, the diabetes had remitted in only ten (10%) of 101 patients tested early (<3 months) compared with 60 (100%) of the 60 later referrals (p<0·0001).

Interpretation: Patients are now referred for genetic testing closer to their presentation with neonatal diabetes. Comprehensive testing of all causes identified causal mutations in more than 80% of cases. The genetic result predicts the best diabetes treatment and development of related features. This model represents a new framework for clinical care with genetic diagnosis preceding development of clinical features and guiding clinical management.

Funding: Wellcome Trust and Diabetes UK.

Copyright © 2015 De Franco et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
The paradigm shift of genetic testing Schematic representation of the steps involved in genetic testing before and after the introduction of next-generation sequencing. The red boxes indicate the role of genetic testing.
Figure 2
Figure 2
Different genetic causes of neonatal diabetes in patients born to non-consanguineous and consanguineous parents Comparison of genetic causes of neonatal diabetes in non-consanguineous (n=790) and consanguineous groups (n=230). Consanguinity is defined by parents being second cousins or more closely related or by the presence of 1·56% or higher total homozygosity. Genes mutated in fewer than 2·5% of patients in both cohorts were grouped in the other category (appendix).
Figure 3
Figure 3
A genetic diagnosis guides clinical management Schematic representation of genetic causes of neonatal diabetes and the implications of this genetic diagnosis. N indicates the number of patients identified with mutations in each of the genes in the 1020 neonatal diabetes patient cohort. Solid arrows indicate implications for most mutations in the genes. Dashed arrows indicate the implications for specific mutations.
Figure 4
Figure 4
Genetic diagnosis precedes development of additional clinical features defining the neonatal diabetes subtype (A) Effect of early genetic diagnosis in transient neonatal diabetes caused by 6q24 methylation defects or potassium channel gene mutations. Bar chart representing clinical features at the time of genetic testing for neonatal diabetes. Orange=diabetes, purple=diabetes remitted. (B) The effect of age at genetic testing on whether patients have non-diabetes features of Wolcott-Rallison Syndrome at the time of referral for genetic testing. Bar chart representing clinical features at the time of genetic testing for neonatal diabetes. Orange=diabetes only, light blue=diabetes and either skeletal abnormalities or liver dysfunction, dark blue=diabetes, skeletal abnormalities, and liver dysfunction. (C) The effect of age at genetic testing on whether patients with a KCNJ11 p.Val59Met mutation have neurological features at the time of referral for genetic testing. Bar chart representing clinical features at the time of genetic testing for neonatal diabetes. Orange=diabetes only, green=diabetes and neurological features.

References

    1. Iafusco D, Massa O, Pasquino B, the Early Diabetes Study Group of ISPED Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. Acta Diabetol. 2012;49:405–408.
    1. Slingerland AS, Shields BM, Flanagan SE. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260?000 live births. Diabetologia. 2009;52:1683–1685.
    1. Edghill EL, Dix RJ, Flanagan SE. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes. 2006;55:1895–1898.
    1. Iafusco D, Stazi MA, Cotichini R, the Early Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology Permanent diabetes mellitus in the first year of life. Diabetologia. 2002;45:798–804.
    1. Gloyn AL, Pearson ER, Antcliff JF. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350:1838–1849.
    1. Proks P, Arnold AL, Bruining J. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet. 2006;15:1793–1800.
    1. Babenko AP, Polak M, Cavé H. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355:456–466.
    1. Sagen JV, Raeder H, Hathout E. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004;53:2713–2718.
    1. Pearson ER, Flechtner I, Njølstad PR, the Neonatal Diabetes International Collaborative Group Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355:467–477.
    1. Codner E, Flanagan S, Ellard S, García H, Hattersley AT. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care. 2005;28:758–759.
    1. Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT, the Neonatal Diabetes International Collaborative Group Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008;31:204–209.
    1. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K, the International Society for Pediatric and Adolescent Diabetes ISPAD Clinical Practice Consensus Guidelines 2006–2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes. 2006;7:352–360.
    1. Bonnefond A, Philippe J, Durand E. Highly sensitive diagnosis of 43 monogenic forms of diabetes or obesity through one-step PCR-based enrichment in combination with next-generation sequencing. Diabetes Care. 2014;37:460–467.
    1. Ellard S, Lango Allen H, De Franco E. Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia. 2013;56:1958–1963.
    1. Gao R, Liu Y, Gjesing AP. Evaluation of a target region capture sequencing platform using monogenic diabetes as a study-model. BMC Genet. 2014;15:13.
    1. Bittles AH. A community genetics perspective on consanguineous marriage. Community Genet. 2008;11:324–330.
    1. Lander ES, Botstein D. Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. Science. 1987;236:1567–1570.
    1. Flanagan SE, Patch AM, Locke JM. Genome-wide homozygosity analysis reveals HADH mutations as a common cause of diazoxide-responsive hyperinsulinemic-hypoglycemia in consanguineous pedigrees. J Clin Endocrinol Metab. 2011;96:E498–E502.
    1. Rubio-Cabezas O, Flanagan SE, Damhuis A, Hattersley AT, Ellard S. KATP channel mutations in infants with permanent diabetes diagnosed after 6 months of life. Pediatr Diabetes. 2012;13:322–325.
    1. Mackay DJ, Temple IK, Shield JP, Robinson DO. Bisulphite sequencing of the transient neonatal diabetes mellitus DMR facilitates a novel diagnostic test but reveals no methylation anomalies in patients of unknown aetiology. Hum Genet. 2005;116:255–261.
    1. Delépine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet. 2000;25:406–409.
    1. Støy J, Edghill EL, Flanagan SE, the Neonatal Diabetes International Collaborative Group Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA. 2007;104:15040–15044.
    1. Garin I, Edghill EL, Akerman I, the Neonatal Diabetes International Group Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. Proc Natl Acad Sci USA. 2010;107:3105–3110.
    1. Shearer AE, DeLuca AP, Hildebrand MS. Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci USA. 2010;107:21104–21109.
    1. Valencia CA, Ankala A, Rhodenizer D. Comprehensive mutation analysis for congenital muscular dystrophy: a clinical PCR-based enrichment and next-generation sequencing panel. PLoS One. 2013;8:e53083.
    1. O'Sullivan J, Mullaney BG, Bhaskar SS. A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J Med Genet. 2012;49:322–326.
    1. Gardner RJ, Mackay DJ, Mungall AJ. An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet. 2000;9:589–596.
    1. Temple IK, Gardner RJ, Robinson DO. Further evidence for an imprinted gene for neonatal diabetes localised to chromosome 6q22-q23. Hum Mol Genet. 1996;5:1117–1121.
    1. Temple IK, Shield JP. Transient neonatal diabetes, a disorder of imprinting. J Med Genet. 2002;39:872–875.
    1. Flanagan SE, Patch AM, Mackay DJ. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes. 2007;56:1930–1937.
    1. Gloyn AL, Reimann F, Girard C. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet. 2005;14:925–934.
    1. Busiah K, Drunat S, Vaivre-Douret L. Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study. Lancet Diabetes Endocrinol. 2013;1:199–207.
    1. Julier C, Nicolino M. Wolcott-Rallison syndrome. Orphanet J Rare Dis. 2010;5:29.
    1. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci USA. 2004;101:17539–17544.
    1. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia. 2006;49:2559–2563.
    1. Shimomura K, Hörster F, de Wet H. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology. 2007;69:1342–1349.
    1. Chatila TA, Blaeser F, Ho N. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000;106:R75–R81.
    1. Barzaghi F, Passerini L, Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol. 2012;3:211.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren